Vantage Point: Big Data

Share this article:
Harris Kaplan
Harris Kaplan

Big Data is coming and with it the danger of pharmaceutical marketers relying on it too heavily as a lens with which to assess physician behavior and prescribing trends.

Physicians dislike Big Data because it flies in the face of personalized medicine. Patients differ in education, income, and language and these variables often affect treatment decisions. Analysis based on averages will lead to step edits, performance metrics, and pay-for-performance schemes that will limit treatment options, hamper physicians' ability to give individualized care, and incentivize suboptimal care.

Every physician has their database of experience and every patient is unique. They rarely fit the averages.  David Ogilvy, the legendary ad guru, once noted, “The consumer is not a moron, she is your wife.” Applying this to healthcare, despite what your loved one learns online, they're not average and you don't want their physician treating them “by the numbers.”

For brand directors, Big Data can help frame health economic and product value arguments to payers. But it doesn't predict physician response to new clinical data, or to a new product. Nor does it persuade a physician trying to maximize the number of patients seen per day that patient education or switching patients to a new drug is worth their time. Only small data, or primary research, can provide that insight.

Individual-level prescribing data transformed pharmaceutical marketing. Big Data is a major step forward in this vein. But marketers should never forget that healthcare is delivered one-to-one and that physicians still reign relative to making prescribing decisions. And each physician and their practice are unique. They're not just data points.


Harris Kaplan is managing partner, Red Team Associates, a division of Healogix.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Vantage Point

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Vantage Point

Vantage Point: Payers—the "experts" in healthcare research

Vantage Point: Payers—the "experts" in healthcare research

Access to payers is about knowledge, about understanding what they do in their jobs

Vantage Point: Determining "fair market value"

Vantage Point: Determining "fair market value"

Should pharma formulate a super matrix to determine the FMV of research incentives?

Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials